

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**202106Orig1s000**

**STATISTICAL REVIEW(S)**



U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Translational Sciences  
Office of Biostatistics

## STATISTICAL REVIEW AND EVALUATION

### CLINICAL STUDIES

**NDA/BLA Serial Number:** 202,106

**Drug Name:** Meropenem for Injection USP and Sodium Chloride Injection USP in the Duplex® Container, 0.5g and 1g

**Indication(s):** Treatment of skin and skin structure infections

**Applicant:** B. Braun Medical Inc.,

**PDUFA Date:** July 27, 2014

**Review Priority:** Standard

**Biometrics Division:** IV

**Statistical Reviewer:** Meg A. Gamalo, Ph.D.

**Concurring Reviewers:** Thamban Valappil, Ph.D.

**Medical Division:** Anti-infective Products

**Clinical Team:** Alma Davidson, MD and Benjamin Lorenz, MD

**Project Manager:** Maureen Dillon-Parker

**Keywords:** 505(b)(2)

## EXECUTIVE SUMMARY

B. Braun Medical Inc., henceforth designated as Sponsor, submits a new drug application (NDA) for the drug product Meropenem for Injection USP and Sodium Chloride Injection USP in the Duplex Container, 0.5g and 1g strength, in accordance with 21 CFR §314.50. Meropenem for Injection USP and Sodium Chloride Injection USP in the Duplex® Container is a parenteral solution intended solely for administration by injection and contains the same active and inactive ingredients [REDACTED] <sup>(b) (4)</sup> as Merrem® that is the subject of an approved full new drug application, NDA 050706 held by Astra Zeneca. Because of this Duplex® packaging system, this NDA is submitted as a 505(b)(2) with Merrem® I.V., in the 0.5g and 1g strengths as the reference listed drug (RLD). According to the electronic Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book), the RLD is not covered by a listed patent and there is no unexpired exclusivity for Merrem® 0.5 g and 1 g vials.

To discuss the 505(b)(2) application, a pre-NDA Type B face-to-face meeting was held on November 4, 2010. The meeting package (MP) was submitted on September 30, 2010. The Division sent preliminary written responses to the Sponsor's questions from the MP on October 26, 2009 via e-mail and minutes of the meeting was sent on November 24, 2010. The overall issues that were discussed pertain to manufacturing and product stability. We defer to the Quality Assessment team for their opinion on the acceptability of the information submitted in this NDA.

There are no clinical studies submitted for review. All appropriate required clinical and preclinical data on Meropenem was filed for Merrem® I.V. and reviewed and approved by the Agency under AstraZeneca's NDA 050706.

## **SIGNATURES/DISTRIBUTION LIST**

Primary Statistical Reviewer: Meg A. Gamalo, Ph.D.

Date:

Statistical Team Leader: Thamban Valappil, Ph.D.

cc:

HFD-520/Maureen Dillon-Parker

HFD-520/Alma Davidson, M.D.

HFD-520/Benjamin Lorenz, M.D.

HFD-725/Meg Gamalo, Ph.D.

HFD-725/Thamban Valappil, Ph.D.

HFD-725/Daphne Lin, Ph.D.

HFD-725/Dionne Price, Ph.D.

HFD-700/OB/Lillian Patrician, MS, MBA

c:\...\NDA202106\NDA202106final.doc

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARGARET A GAMALO  
04/30/2014

THAMBAN I VALAPPIL  
05/12/2014

## STATISTICS FILING CHECKLIST FOR A NEW NDA/BLA

**NDA Number:**

202106

**Applicant:**

B. Braun Medical Inc.,

**Stamp Date:**

27 September 2013

Meropenem for Injection USP  
and Sodium Chloride Injection  
USP in the Duplex® Container,  
0.5g and 1g

**NDA/BLA Type:**

NDA, Standard Review (PDUFA IV)

On **initial** overview of the NDA/BLA application for refuse to file (RTF):

	<b>Content Parameter</b>	<b>Yes</b>	<b>No</b>	<b>NA</b>	<b>Comments</b>
1	Index is sufficient to locate necessary reports, tables, data, etc.	✓			
2	ISS, ISE, and complete study reports are available (including original protocols, subsequent amendments, etc.)			✓	
3	Safety and efficacy were investigated for gender, racial, and geriatric subgroups investigated.			✓	
4	Data sets in EDR are accessible and conform to applicable guidances (e.g., existence of define.pdf file for data sets).			✓	

**IS THE STATISTICAL SECTION OF THE APPLICATION FILEABLE? Yes**

## STATISTICS FILING CHECKLIST FOR A NEW NDA/BLA

Please identify and list any potential review issues to be forwarded to the Applicant for the 74-day letter.

Content Parameter (possible review concerns for 74-day letter)	Yes	No	NA	Comment
Designs utilized are appropriate for the indications requested.			✓	
Endpoints and methods of analysis are specified in the protocols/statistical analysis plans.			✓	
Interim analyses (if present) were pre-specified in the protocol and appropriate adjustments in significance level made. DSMB meeting minutes and data are available.			✓	
Appropriate references for novel statistical methodology (if present) are included.			✓	
Safety data organized to permit analyses across clinical trials in the NDA/BLA.			✓	
Investigation of effect of dropouts on statistical analyses as described by applicant appears adequate.			✓	

Remark: There are no clinical studies submitted for review. All appropriate required clinical and preclinical data on Meropenem was filed for Merrem® I.V. and reviewed and approved by the Agency under AstraZeneca's NDA 050706.

Meg A. Gamalo, PhD  
 \_\_\_\_\_  
 Reviewing Statistician

Date

Thamban Valappil, PhD  
 \_\_\_\_\_  
 Team Leader

Date

File name: 5\_Statistics Filing Checklist for a New NDA\_BLA (b) (4)

**STATISTICS FILING CHECKLIST FOR A NEW NDA/BLA**

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARGARET A GAMALO  
11/20/2013

THAMBAN I VALAPPIL  
11/20/2013